Syncona Limited

Declaration of Voting Results & Voting Rights Announcements • Apr 2, 2024

National Storage Mechanism | Additional information

RNS Number : 0067J

Syncona Limited

02 April 2024

Syncona Limited

Total Voting Rights

2 April 2024

Pursuant to DTR 5.6.1 Syncona Limited (the "Company") announces that as at 31 March 2024 the total number of ordinary shares in issue stands at 671,806,666. The Company holds 16,471,080 ordinary shares in treasury which attract no voting rights.

Therefore, the total number of voting rights in the Company is 655,335,586. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

Enquiries

Syncona Ltd

Annabel Clark 

Tel: +44 (0)   7714 916615

FTI Consulting

Ben Atwell / Natalie Garland-Collins / Tim Stamper

Tel: +44 (0) 20 3727 1000 

About Syncona

Syncona's purpose is to invest to extend and enhance human life. We do this by creating and building companies to deliver transformational treatments to patients in areas of high unmet need.

Our strategy is to create, build and scale companies around exceptional science to create a diversified portfolio of 20-25 globally leading healthcare businesses, across development stage and therapeutic areas, for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRFLFVVSEIFIIS